drugset / Trial / NCT00620776
Combined Treatment for Generalized Anxiety Disorder (GAD)
Phase 2
Completed
69 enrolled
University of Pennsylvania
National Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to conduct a preliminary evaluation of the efficacy of combined medication and psychotherapy for generalized anxiety disorder (GAD). The general goals of the current study are to conduct a late stage treatment development study. The goal of this stage of research is to provide a preliminary answer to the question and to gather data to estimate intervention parameters (e.g., effect size, attrition rates, response rates) that would assist in planning further research.
Timeline
- Start
- 2006-10
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venlafaxine | Small molecule | 150 mg | Oral |
| Subject | Venlafaxine | Small molecule | 225 mg | Oral |